Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease c syndrome
Phenotype C0027051|myocardial infarct
Sentences 20
PubMedID- 25789257 Objectives: in the present study we aimed to compare myocardial infarction size in patients with metabolic syndrome to those without metabolic syndrome using peak ck-mb and cardiac troponin i (ctni) at 72 hours after the onset of symptoms.
PubMedID- 21757819 Background: the purpose of the present study was to compare the efficacy and safety of paclitaxel-eluting stent (pes), sirolimus-eluting stent (ses), and zotarolimus-eluting stent (zes) in primary percutaneous coronary intervention (pci) for acute st-segment elevation myocardial infarction (stemi) with metabolic syndrome (ms).
PubMedID- 23411742 Aim of this study was to determine the prevalence of metabolic syndrome in patients with premature myocardial infarction (before 50 years of age).
PubMedID- 19356813 Obesity and the metabolic syndrome in patients with acute myocardial infarction.
PubMedID- 20811489 Prevalence, detection, and management of the metabolic syndrome in patients with acute myocardial infarction: role of an obesity-centric definition.
PubMedID- 22263382 Metabolic syndrome and outcome in patients with acute myocardial infarction.
PubMedID- 22971940 Presence of metabolic syndrome is associated with larger myocardial infarction size and complications following acute myocardial infarction.
PubMedID- 23934969 Objective: this study aimed to evaluate long-term survival according to the presence of metabolic syndrome (ms) in patients with acute myocardial infarction (ami) undergoing successful percutaneous coronary intervention (pci) with drug-eluting stents (des).
PubMedID- 20890426 We sought to determine the prevalence of metabolic syndrome (ms) in patients with acute myocardial infarction and its effect on clinical outcomes.
PubMedID- 22701134 The aim of this study was to evaluate clinical impact of non-hdl-c and apob on clinical outcomes in metabolic syndrome (ms) patients with acute myocardial infarction (ami) undergoing percuatneous coronary intervetion.
PubMedID- 21159478 Acute inferior myocardial infarction with nephrotic syndrome.
PubMedID- 23715346 The study was aimed to find out the impact of metabolic syndrome in patients with acute myocardial infarction during hospital stay.
PubMedID- 21487455 Patient was diagnosed with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, further complicated by non-st elevation myocardial infarction (nstemi), and acute pancreatitis based on the peripheral smear, thrombocytopenia, hemolytic anemia, acute renal failure, elevated cardiac biomarkers and elevated pancreatic enzymes.
PubMedID- 21428179 Conclusion: elevated homocysteine levels were correlated to the metabolic syndrome in patients with prior myocardial infarction.
PubMedID- 21129152 It also reduced the risk of myocardial infarction in patients with severe metabolic syndrome by 56% (8 year follow-up) and the development of type 2 diabetes by almost half (2 and 5 year follow-up) [26].
PubMedID- 24020829 Intra-thoracic fat volume is associated with myocardial infarction in patients with metabolic syndrome.
PubMedID- 20509277 Aim: to analyze the components of metabolic syndrome from patients with cardiovascular disease (myocardial infarction).
PubMedID- 25563711 Effect of angiotensin converting enzyme inhibitors on periprocedural myocardial infarction in patients with metabolic syndrome.
PubMedID- 22240598 Coronary artery bypass grafting for multivessel coronary artery disease in metabolic syndrome patients with acute myocardial infarction.
PubMedID- 21646744 Heart failure mimicking prior myocardial infarction in a patient with idiopathic hypereosinophilic syndrome.

Page: 1